Compare Zimmer Biomet Holdings Inc (ZBH) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Zimmer Biomet Holdings Inc vs Zeta Global Holdings Corp — how do they compare? Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2× Zeta Global Holdings Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Zimmer Biomet Holdings Inc for 89 Days and Zeta Global Holdings Corp for 19 Days on average.
| ZBH | ZETA | |
|---|---|---|
Market Cap | $16.95B | $8.29B |
Volume | 2,505,240 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $103.98 | $33.74 |
52-Week Low | $79.58 | $14.55 |
Typical Hold Time | 89 Days | 19 Days |
Enterprise Value | $24.02B | $8.18B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
ZETA trades at $33.09, down 1.93% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and support at $32. Fundamentally, revenue grew to $1.3B in 2025 with a gross margin of 59.48%, but net income remains negative. Recent quarters saw EPS beats, and the company is expanding internationally with a new UK hub. Analyst sentiment is positive with 12 buy ratings and a $32.40 consensus target.
The outlook is cautiously optimistic due to strong revenue growth and AI-driven customer adoption, but profitability risks persist with negative net margins and high valuation multiples. Investors should weigh growth potential against execution risks and competitive pressures in the tech services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
